Health Catalyst, Inc.
HCATHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeHealth Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. At a $127.2M market cap, Health Catalyst, Inc. ranks as a micro-cap company within healthcare. The company operates in two segments: Technology and Professional Services.
Market Cap
$127.2M
Beta
1.54
P/E (TTM)
—
P/E (Fwd)
225.33
EPS (TTM)
$-3.69
EPS (Fwd)
$0.01
ROE
-118.1%
ROA
-3.0%
Cash
$103.4M
Total Debt
$170.0M
Free CF
-$48.6M
52W Change
-47.8%
Annual Financials
Cash vs Debt
Where HCAT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HCAT finished 3.64% above its 150-day moving average ($1.65) and 2.29% below its 200-day moving average ($1.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HCAT overbought or oversold?
At the October 20, 2026 close, HCAT's RSI(14) was 44.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $103.4M in cash, though total debt stands at $170.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$48.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -118.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $276.2M to $311.1M.
With a beta above 1.5, HCAT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HCAT.